Top Ten most popular articles on Pharmafile.com this week!
pharmafile | May 17, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | BMS, Gilead, J&J, JJ, Janssen, Mundipharma, Novartis, Teva, generics
Some big names – including Gilead, Janssen, Teva and Bristol-Myers Squibb – were in trouble this week after two separate lawsuits accused them and others of suppressing competition. While Gilead had sought to retain dominance in the HIV drugs market, Teva was alleged to be at the centre of a conspiracy through which generic drugmakers divided up the market for generic meds.
On the other hand, are top story covered Novartis exec Jerome Moreau’s move to Mundipharma as he took on the role of Head of Access at the firm. Talking of access, NHS England agreed to pay for Biogen’s incredibly expensive SMA treatment Spinraza – sold in the US for $750,000 a year. For all of this and more, check out this week’s top ten on Pharmafile.com!
10. Novartis buys dry eye treatment Xiidra in deal worth $5.3 billion
Japanese multinational Takeda Pharmaceutical has agreed to sell its dry eye drug Xiidra to Swiss firm Novartis in a deal worth as much as $5.3 billion.
9. Two Daiichi Sankyo drugs dealt a thumbs up and thumbs down by FDA advisory panel
Daiichi Sankyo was left with a bittersweet taste in its mouth after it saw one of its drugs recommended for FDA approval by the US agency’s Oncologic Drugs Advisory Committee (ODAC), but another of its products was turned down.
8. Gilead struck anti-competitive deals to retain dominance in HIV market, lawsuit says
Gilead Sciences struck anti-competitive deals with Janssen and Britsol-Myers Squibb in an effort to retain dominance in the market for HIV drugs, according to a lawsuit filed by AIDS activists and unions.
7. NHS England agree to pay for Biogen’s $750,000 a year SMA treatment Spinraza
NHS England has agreed to pay an undisclosed price for Biogen’s spinal muscle atrophy (SMA) treatment Spinraza.
6. Clinical trial will test long acting HIV injection
A long-acting, injectable HIV drug combo is to be tested in a clinical trial of 350 volunteers with HIV.
5. Eli Lilly’s Emgality shows positive Phase 3 results in treatment of migraine
Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the treatment of episodic migraine.
4. US States allege 20 generic drugmakers fixed prices of generic drugs
Forty-four US States have filed a lawsuit against 20 generic drugmakers – including Teva Pharmaceuticals – over allegations the firms fixed prices and stifled competition for generic meds.
The FDA has revealed that it plans to terminate its “alternative summary reporting” programme which has allowed the manufacturers of medical devices to keep undesirable reports of malfunctions and adverse events out of public knowledge.
2. The interplay between the GDPR and the EU Clinical Trials Regulation
Paul Kavanagh, partner at law firm Dechert, explores the relationship between GDPR and CTR, and its potential impact on the legal implications of personal clinical trial data processing and handling.
1. Ex-GSK, Novartis exec named as Mundipharma’s Head of Access
Mundipharma has announced that Jerome Moreau has joined the company as its new Head of Market Access.
Related Content
Gilead’s HIV treatment meets primary trial endpoint
Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a …
Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …
Gilead announces first shipments of HIV prevention drug to Eswatini and Zambia
Gilead has announced the first shipments of its HIV prevention drug lenacapavir to Eswatini and …
